Search
Methionine
go.drugbank.com/drugs/DB00134ApprovedInvestigationalNutraceuticalA sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals.
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 MLSynonyms: MetDacarbazine
go.drugbank.com/drugs/DB00851ApprovedInvestigationalAn antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). … Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Products: DACARBAZINA 200 MG, DACARBAZINA 100 MGMetamizole
go.drugbank.com/drugs/DB04817ApprovedInvestigationalWithdrawnIt is considered a potent analgesic and antipyretic with favourable gastrointestinal tolerability. … [A251805] Metamizole is still used in certain countries in Europe, Asia and South America.[A251805]
Mixtures: N-BUTIL BROMURO DE HIOSCINA20MG + DIPIRONA 2500 MG/5 ML, DIPIRONA SODICA 2.5G/5ML + N- BUTILBROMURO DE HIOSCINA 20 MG/5ML SOLUCION INYECTABLEProducts: METAMIZOL - CT 500MG, METLINA 5 MG TABLETASEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalIt is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism … be on lifelong therapy.
Products: LIXIANA 15 MG, LIXIANA 30 MGIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … Although available as a single dose tablet, elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.
Mixtures: GENVOYA FILM COATED TABLET 150 MG/150 MG/200 MG/10 MG, STRIBILD FILM COATED TABLET 150 MG/150 MG/200 MG/245 MGCategories: Antivirals used in combination for the treatment of HIV infectionsAMG-337
go.drugbank.com/drugs/DB15639InvestigationalAMG-337 is under investigation in clinical trial NCT03147976 (QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors).
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawn[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … It is a complex mixture of the free fatty acids form containing eicosapentaenoic acid and docosahexaenoic acid as the most abundant species found in a proportion of 55% and 20% respectively.
Nilotinib
go.drugbank.com/drugs/DB04868ApprovedInvestigational), another tyrosine kinase inhibitor used as a first-line treatment for CML. … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec
Products: TASIGNA (200 MG), TASIGNA® 150 MG CAPSULASPhenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIn the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]
Mixtures: AZOSILIN 500 MG/50 MG TABLET, 12 ADET, AZOSILIN 500 MG/50 MG TABLET, 30 ADETProducts: UROXACIN®200 MG, UROGESIC TABLET 100 mg